Literature DB >> 3904167

Increasing incidence of resistance to gentamicin and related aminoglycosides in Salmonella typhimurium phage type 204c in England, Wales and Scotland.

E J Threlfall, B Rowe, J L Ferguson, L R Ward.   

Abstract

Phage type 204c of Salmonella typhimurium (DT 204c) appeared in bovine animals in 1979. It is now the predominant type in cattle in England, Wales and Scotland and ranks in the 10 most common phage types in humans. All strains of DT 204c have been resistant to at least four antimicrobial drugs. In 1979 and 1980 the most common resistance pattern was that of chloramphenicol, streptomycin, sulphonamides, tetracyclines and trimethoprim (CSSuTTm) but since 1981 strains with additional resistance to ampicillin and neomycin-kanamycin (AK) have predominated. Strains resistant to furazolidone (Fu) have caused sporadic outbreaks. Gentamicin resistance (G) appeared in DT 204c in 1983 and gentamicin-resistant strains are increasing in incidence. With the exception of resistance to furazolidone, drug resistance in DT 204c has been plasmid-mediated. Characterisation of gentamicin resistance plasmids in DT 204c of R-type ACGKSSuTTm has demonstrated the existence of three distinct lines, two of which have been found exclusively in cattle and one in cattle and humans. The misguided and often inappropriate use of antimicrobial drugs in calves has contributed to the appearance of multiresistant strains of DT 204c and positive measures to limit range and levels of antimicrobials available to feed manufacturers may be necessary.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3904167     DOI: 10.1136/vr.117.14.355

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  9 in total

Review 1.  Salmonella enterica serotype Typhimurium and its host-adapted variants.

Authors:  Wolfgang Rabsch; Helene L Andrews; Robert A Kingsley; Rita Prager; Helmut Tschäpe; L Garry Adams; Andreas J Bäumler
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

2.  Diversity and molecular variation among plasmids in Salmonella enterica serotype Dublin based on restriction enzyme fragmentation pattern analysis.

Authors:  L M Browning; C Wray; D J Platt
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

3.  Antimicrobial resistance among Salmonella serovars isolated from different sources in Brazil during 1978-1983.

Authors:  L C Campos; E Hofer
Journal:  Antonie Van Leeuwenhoek       Date:  1989-04       Impact factor: 2.271

4.  Apramycin and gentamicin resistance in Escherichia coli and salmonellas isolated from farm animals.

Authors:  C Wray; R W Hedges; K P Shannon; D E Bradley
Journal:  J Hyg (Lond)       Date:  1986-12

5.  Characterization of plasmids conferring resistance to gentamicin and apramycin in strains of Salmonella typhimurium phage type 204c isolated in Britain.

Authors:  E J Threlfall; B Rowe; J L Ferguson; L R Ward
Journal:  J Hyg (Lond)       Date:  1986-12

6.  Human isolates of apramycin-resistant Escherichia coli which contain the genes for the AAC(3)IV enzyme.

Authors:  J E Hunter; C A Hart; J C Shelley; J R Walton; M Bennett
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

7.  Gentamicin-resistant Salmonella typhimurium phage type 204c: molecular studies and strain diversity in a putative bovine outbreak.

Authors:  D J Platt; I Smith
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

8.  Antibiotic resistance in Salmonella enterica serotype typhimurium.

Authors:  U Gross; H Tschäpe; I Bednarek; M Frosch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

9.  Multidrug-resistant Salmonella typhimurium, Pacific Northwest, United States.

Authors:  Margaret A Davis; Thomas E Besser; Kaye Eckmann; Kathryn MacDonald; Donna Green; Dale D Hancock; Katherine N K Baker; Lorin D Warnick; Yesim Soyer; Martin Wiedmann; Douglas R Call
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.